Descriptive only
eGFR total slope
Type 2 diabetes (adults)
longest follow-up from week 52Not stated by the trialsEach dose separatelyMean difference
1
Randomized trials
4
Treatments
1,428
Participants
4
Trial arms
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 1 of 1 | Albuminuria (mg/g) prognostic factor; 1 of 1 |
|---|---|---|
| SURPASS-6 S000108 | 89.03 | 26.44 mean |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteData handling, input conversions: n_randomized 4
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SURPASS-6 | 52 | safety | eGFR change from baseline to week 52, one year total change | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2020 | adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| SURPASS-6 | A1 | TIRZ_SC_5MG_QW | 52 | arm, change | -3.600 | 0.650 | 243 | n_randomized | R0009666:Supplement eTable 14 |
| SURPASS-6 | A2 | TIRZ_SC_10MG_QW | 52 | arm, change | -2.800 | 0.660 | 238 | n_randomized | R0009666:Supplement eTable 14 |
| SURPASS-6 | A3 | TIRZ_SC_15MG_QW | 52 | arm, change | -1.900 | 0.660 | 236 | n_randomized | R0009666:Supplement eTable 14 |
| SURPASS-6 | A4 | INS_LISPRO | 52 | arm, change | -2.700 | 0.390 | 711 | n_randomized | R0009666:Supplement eTable 14 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.